Shalini Sharp, MBA

Shalini Sharp currently serves on the Boards of Directors of Neurocrine Biosciences and Organon & Co. Previously, Shalini served on the Boards of Directors of Mirati Therapeutics (prior to its acquisition by Bristol Myers Squibb), Sutro Biopharma, Precision Biosciences, Array Biopharma (prior to its acquisition by Pfizer), Panacea Acquisition Corp. (prior to its merger with Nuvation Bio.), and Agenus Inc.

Shalini has held positions as Chief Financial Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases, and Chief Financial Officer at Agenus, a clinical-stage immuno-oncology company. Shalini previously held positions at Elan Pharmaceuticals, McKinsey & Company, and Goldman Sachs.

Shalini holds a BA and an MBA from Harvard University.